Experience of long-term afala treatment in benign prostatic hyperplasia.
The use of ultralow doses of antibodies to prostate-specific antigen (afala) for long-term treatment of benign prostatic hyperplasia in patients with moderate symptoms rapidly and effectively reduces irritative and obstructive symptoms, significantly decreases residual urine volume, and increases the rate of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms.
Gudkov
A V
AV
Siberian State Medical University, Federal Agency for Health Care and Social Development, Tomsk.
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
D000906:Antibodies; D007155:Immunologic Factors; C533336:afala